Uveitis Gene-Expression Profiling

NCT ID: NCT00874471

Last Updated: 2014-04-09

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 280 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2005-06-30

Brief Summary

Uveitis is a group of troublesome diseases that collectively represent a cause of blindness comparable to diabetes. Most forms of uveitis are either infectious or immune-mediated. The investigators propose to create a data base on peripheral blood gene expression for patients with 3 of the most important diseases associated with uveitis: ankylosing spondylitis, sarcoidosis, and Behcet's disease. The investigators will quantitatively measure the expression of consistent alteration in peripheral blood from patients with more than 40,000 gene sequences using microarray gene chip technology. This approach is known to detect systemic immune-mediated disease. The investigators will use this data base to:

1. Determine if patients with uveitis and ankylosing spondylitis, sarcoidosis, or Behcet's can be distinguished from a normal population or controls with the same systemic disease but no history of uveitis

2. Determine if the profile of gene expression can distinguish infectious or idiopathic forms of uveitis from patients with spondylitis, sarcoidosis, or Behcet's

3. Determine how this gene profile changes over time as episodic disease such as spondylitis or Behcet's activates or remits

4. Correlate the changes in gene expression with the prognosis of the ocular inflammatory process.

The creation of a gene expression data base for patients with uveitis has the potential to clarify the pathogenesis of disease, establish new diagnostic tools, and provide a means for predicting prognosis.

Conditions

Uveitis

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

sarcoidosis

No interventions assigned to this group

ankylosing spondylitis

No interventions assigned to this group

Behcet's disease

No interventions assigned to this group

toxoplasmosis

No interventions assigned to this group

herpetic acute retinal necrosis

No interventions assigned to this group

idiopathic uveitis

No interventions assigned to this group

ankylosing spondylitis (no uveitis)

No interventions assigned to this group

sarcoidosis (no uveitis)

No interventions assigned to this group

Behcet's disease (no uveitis)

No interventions assigned to this group

normal control

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• The study group will include patients aged 21 years or older attending the Uveitis Clinic at the Casey Eye Institute at OHSU who have uveitis of the following subtypes:

1. ankylosing spondylitis

2. sarcoidosis

3. Behçet's disease

4. toxoplasmosis

5. herpetic acute retinal necrosis; AND

6. idiopathic uveitis

• Another group of patients, also aged 21 years or more, with the following diseases but no uveitis, will be recruited from the Rheumatology Clinic at OHSU as follows:

1. ankylosing spondylitis

2. sarcoidosis; AND

3. Behçet's disease

• The study group will also include 30 normal control volunteers aged 21 years or older.

Exclusion Criteria

• Special/vulnerable subject populations (e.g., mentally impaired persons and children) will not be enrolled.

• Minimum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Oregon Health and Science University

OTHER

Sponsor Role: lead

Responsible Party

Jim Rosenbaum

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

James Rosenbaum, MD

Role: PRINCIPAL_INVESTIGATOR

Oregon Health and Science University

Locations

Oregon Health & Science University

Portland, Oregon, United States

Countries

United States

Other Identifiers

R01EY015858

Identifier Type: NIH

Identifier Source: org_study_id

View Link